Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026

Avalo Therapeutics, Inc.

2025-Q2 EPS reported -$3.18 vs consensus -$1.43 ▼ miss (-121.9%)

Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.
Cash and short-term investments $113.3M as of June 30, 2025; expected to fund operations into 2028.
Phase 2 LOTUS trial (AVTX-009 in hidradenitis suppurativa) enrollment >75% complete; topline data expected mid-2026.
R&D expenses increased to $14.1M from $4.6M, largely due to the Phase 2 LOTUS trial.
Rita Jain, M.D. appointed to Board of Directors; brings clinical development and regulatory experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.